ProCE Banner Activity

How I Use Blinatumomab and Inotuzumab Ozogamicin in Patients With Relapsed/Refractory ALL

Clinical Thought
Here’s my take on how patient-specific factors and ultimate treatment goals direct selection of therapy for patients with R/R ALL.

Released: September 30, 2020

Expiration: September 29, 2021

Share

Faculty

David Marks

David Marks, MD, PhD

Professor of Haematology and Stem Cell Transplanation
Department of Haematology and BMT
University of Bristol
University Hospitals Bristol NHS
Bristol, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

David Marks, MD, PhD

Professor of Haematology and Stem Cell Transplanation
Department of Haematology and BMT
University of Bristol
University Hospitals Bristol NHS
Bristol, United Kingdom

David Marks, MD, PhD, has disclosed that he has received consulting fees from Amgen, Novartis, and Pfizer.